Be part of the only event that brings together those prioritizing target discovery of ADCs at pharma, biotech and research institutes.

Be Part of the Only Event Dedicated to Progressing How ADC Developers Think About Targets

Target selection is the first most important decision to be made during the drug development process.

With three-days of content carefully created to provide you with the complete toolkit to confidently pair target and linker-payload, here are some of the sessions on the 2022 agenda that were not to be missed:


Tubulis GmbH presented on the Tubutecan Platform: Technology-enabled Payload Solutions Targeting Topoisomerase-I where they explored how an in vitro screening technology aids in the design of optimal combination of linker-payload and DAR with target properties


Heidelberg Pharma Research GmbH delved into how Del(17p) can act as a potential platform-wide predictive biomarker for amanitin based ADCs, and how this impacted patient selection in the clinic


Bristol-Myers Squibb outlined how to design site-specific ADCs to maximize target-mediated payload delivery and how characterization of site-specific ADCs can guide constructed design for maximizing target-dependent delivery


AbbVie explored design considerations for an immunology ADC through identification of the antibody target and parameters for selection and how to modify the ADC to maximize the therapeutic index

Grab your copy of the complete 2022 event guide to view the agenda and speaker line-up from last year's event.

If you are going to make one correct decision during the drug development process, selecting the right target is crucial for clinical success. Make sure you don’t miss out and get left behind by your peers as the ADC field advances at a rapid pace.